ライフサイエンスコーパス: areata

1 T cell-mediated hair loss disease (alopezia areata).

2 whereas 39 of 44 controls developed alopecia areata.

3 didate genes in the pathogenesis of alopecia areata.

4 ing the use of these treatments for alopecia areata.

5 similar to those observed in human alopecia areata.

6 erstanding of the genetic basis for alopecia areata.

7 for decubitus ulcer, and 0.01% for alopecia areata.

8 d arthritis, atopic dermatitis, and alopecia areata.

9 e treatment of warts, melanoma, and alopecia areata.

10 vancing the therapeutic pipeline of alopecia areata.

11 juvenile idiopathic arthritis, and alopecia areata.

12 tients aged 12 years and older with alopecia areata.

13 mation that targets anagen hairs in alopecia areata.

14 kinase inhibitor, in patients with alopecia areata.

15 tive, SCD-153, for the treatment of alopecia areata.

16 being explored for the treatment of alopecia areata.

17 agent for limited patchy childhood alopecia areata.

18 igh-incidence model for spontaneous alopecia areata.

19 s a key step in the pathogenesis of alopecia areata.

20 buting factor in the development of alopecia areata.

21 fluvium, androgenetic alopecia, and alopecia areata.

22 s potentially associated with human alopecia areata.

23 C57BL/6J mice do not develop alopecia areata.

24 ng this locus as being important in alopecia areata.

25 he IL-1RN and various phenotypes of alopecia areata.

26 n grafts from mice with spontaneous alopecia areata.

27 ic inflammatory diseases, including alopecia areata.

28 atitis, 0.97 (95% CI, 0.65-1.46) in alopecia areata, 0.90 (95% CI, 0.49-1.65) in vitiligo, 1.64 (95%

29 1.83 in atopic dermatitis, 0.94 in alopecia areata, 0.93 in vitiligo, 1.65 in HS and 1.53 in CISD ov

30 lymphoma (1.85[1.66-2.06], RD0.02), Alopecia Areata (1.77[1.71-1.83], RD0.2), Crohn's disease (1.62[1

31 ype 1 diabetes, coeliac disease and alopecia areata(1,2).

32 ], rosacea [2.85 (2.79, 2.92)], and alopecia areata [2.81 (2.61, 3.03)].

33 ic alopecia (37.3 128.4, 46.1]) and alopecia areata (24.9 [17.2, 32.6]) were statistically significan

34 pic dermatitis [2.46 (2.40, 2.53)], alopecia areata [3.47 (3.24, 3.71)], contact dermatitis [1.92 (1.

35 We aimed to determine the risk of alopecia areata (AA) and vitiligo associated with atopic dermatit

36 Vitiligo and alopecia areata (AA) are common autoimmune conditions characteriz

37 The mechanisms driving alopecia areata (AA) are still unclear, hindering development of

38 ir regrowth in patients with severe alopecia areata (AA) at week 36 of treatment.

39 Alopecia areata (AA) has a high prevalence worldwide and causes c

40 Alopecia areata (AA) has been associated with multiple comorbidit

41 Treatments for alopecia areata (AA) have evolved over the decades from broad and

42 However, vitiligo and alopecia areata (AA) have not been well characterized in the chro

43 g been appreciated that episodes of alopecia areata (AA) have occurred after severely stressful life

44 universalis is an uncommon form of alopecia areata (AA) involving hair loss over the entire scalp an

45 Alopecia areata (AA) is a chronic, nonscarring hair-loss disorder

46 Alopecia areata (AA) is a common autoimmune disease resulting fro

47 Alopecia areata (AA) is a common T cell-mediated disorder with li

48 Alopecia areata (AA) is a complex immune-mediated disorder that c

49 Alopecia areata (AA) is a genetically determined, immune-mediated

50 Alopecia areata (AA) is a non-scarring inflammatory hair loss dis

51 Alopecia areata (AA) is among the most highly prevalent human aut

52 Alopecia areata (AA) is among the most prevalent autoimmune disea

53 Alopecia areata (AA) is an autoimmune disease characterized by ha

54 Alopecia areata (AA) is an autoimmune disease defined by hair los

55 Alopecia areata (AA) is an autoimmune disease of the hair follicl

56 Alopecia areata (AA) is an autoimmune disease that attacks anagen

57 Alopecia areata (AA) is an autoimmune disease that targets active

58 Alopecia areata (AA) is an autoimmune disorder of hair loss with

59 Alopecia areata (AA) is an autoimmune disorder of the hair follic

60 Alopecia areata (AA) is an autoimmune hair loss disorder with no

61 Alopecia areata (AA) is characterized by hair loss in patches and

62 Alopecia areata (AA) is characterized by hair loss ranging from p

63 Alopecia areata (AA) is characterized by immune dysregulation in

64 Alopecia areata (AA) is characterized by nonscarring hair loss of

65 Characterizing blood profile of alopecia areata (AA) is important not only for treatment advancem

66 Alopecia areata (AA) is one of the most common forms of human hai

67 Patients with alopecia areata (AA) may experience episodic disease flares chara

68 y investigated frontiers in current alopecia areata (AA) pathobiology research, with an emphasis on p

69 Treatments for alopecia areata (AA) patients with extensive scalp hair loss are

70 Pediatric alopecia areata (AA) prevalence and incidence data are key to und

71 Although alopecia areata (AA) severity is often defined by the degree of s

72 Current measures of alopecia areata (AA) severity, such as the Severity of Alopecia T

73 dermatitis (AD) among patients with alopecia areata (AA) using data from the Merative MarketScan Rese

74 Alopecia areata (AA), a non-scarring inflammatory hair loss disor

75 m both humans and C3H/HeJ mice with alopecia areata (AA), a T cell-mediated autoimmune disease of the

76 Prevalences of alopecia areata (AA), alopecia totalis (AT), and alopecia univers

77 uraging results in the treatment of alopecia areata (AA), an autoimmune form of hair loss, in small,

78 ety and depression in patients with alopecia areata (AA), as well as a positive association of AA wit

79 ype 1 (ILC1) in the pathogenesis of alopecia areata (AA), because we found them to be significantly i

80 patients under TNFi therapy develop alopecia areata (AA), the most common inflammatory hair loss dise

81 Alopecia areata (AA)-like hair loss in C3H/HeJ mice provides an e

82 most severe and disabling types of alopecia areata (AA).

83 eased in patients with vitiligo and alopecia areata (AA).

84 y of Alopecia Tool (SALT) score for alopecia areata (AA).

85 was reported to play a key role in alopecia areata (AA).

86 iseases (atopic dermatitis [AD] and alopecia areata [AA]).

87 Serum from 38 alopecia areata/AA, 41 atopic dermatitis/AD, 21 psoriasis, 18 hid

88 5, and July 1, 2020, using keywords alopecia areata, acne, atopic dermatitis, lichen planus, psoriasi

89 Alopecia areata affected and resistant mice were characterized to

90 Grafting alopecia areata affected C3H/HeJ mouse skin to littermates induce

91 In alopecia areata affected humans, 95 genes were significantly modu

92 lus, but only lymph node cells from alopecia areata affected mice displayed an increased response wit

93 s, lymph node and spleen cells from alopecia areata affected mice injected into normal haired litterm

94 4+ CD8+ expressing cells in chronic alopecia areata affected mice using monoclonal antibodies permitt

95 Alopecia areata affected skin contained increased numbers of CD4+

96 ll-mediated autoimmune disease, but alopecia areata affected skin graft hosts may resist alopecia are

97 Of 44 mice that received alopecia areata affected skin grafts but failed to develop alopec

98 a, only two of 22 receiving further alopecia areata affected skin grafts developed alopecia areata, w

99 s clinic, 2 to 16 years of age with alopecia areata affecting at least 10% of scalp surface area, wer

100 Alopecia areata affects 1%-2% of the population and is hypothesiz

101 Alopecia areata also has a major negative impact on quality of li

102 For comparison, skin biopsies from alopecia areata and androgenetic alopecia affected humans were al

103 tients aged 12 years and older with alopecia areata and at least 50% scalp hair loss were randomly as

104 peutic techniques for patients with alopecia areata and further refine which subtypes of the disease

105 mmunopathogenic association between alopecia areata and hair color.

106 disease, thyroid disease, vitiligo, alopecia areata and inflammatory bowel disease) were self-reporte

107 Among ASD subtypes, alopecia areata and Sjogren syndrome were consistently associated

108 , in which the outcome variable was alopecia areata and the main predictor was natural hair color bef

109 g psoriasis, atopic dermatitis, and alopecia areata) and eight other immune-mediated diseases and obt

110 ated with Crohn disease, psoriasis, alopecia areata, and leprosy.

111 atosus, Sjogren syndrome, vitiligo, alopecia areata, and multiple sclerosis) and each individual auto

112 gen, such as androgenetic alopecia, alopecia areata, and telogen effluvium.

113 ditions, such as atopic dermatitis, alopecia areata, and vitiligo, but there is a current US Food and

114 dominantly acne, atopic dermatitis, alopecia areata, and vitiligo, only 27.0% had T scores less than

115 itiligo," "seborrheic dermatitis," "alopecia areata," and "lichen planus." Diverse study populations

116 es of 110 patients and 45 controls: alopecia areata, ankylosing spondylitis, dermatomyositis, Graves'

117 Atopic dermatitis (AD) and alopecia areata are highly prevalent inflammatory skin/hair condi

118 essing this TCR develop spontaneous alopecia areata at nearly 100% incidence.

119 observed between IL-1RN and patchy alopecia areata but it was not statistically significant (p =0.06

120 J mouse skin to littermates induces alopecia areata, but high dietary soy oil reduces alopecia areata

121 In a rodent model, alopecia areata can be induced in normal haired C3H/HeJ mice by t

122 t 2% of people over their lifetime, alopecia areata can present with a range of clinical features, fr

123 en atopic dermatitis, vitiligo, and alopecia areata, challenging previously established notions of th

124 s exhibited significantly decreased alopecia areata compared with those with light brown hair (aOR, 0

125 downregulated during onset of mouse alopecia areata consistent with an inflammatory cell-mediated dis

126 psoriasis, acne vulgaris, pruritus, alopecia areata, decubitus ulcer, urticaria, scabies, fungal skin

127 rds the graft, it is suggested that alopecia areata develops as a consequence of an inappropriate imm

128 successfully identify a significant Alopecia Areata disease-relevant gene, KRT82, and reveal a propos

129 Seven PROMs (Scale of Alopecia Areata Distress, AAPPO, and all 5 symptom-based PROMs) f

130 Three PROMs (Scale of Alopecia Areata Distress, Alopecia Areata Quality of Life Index,

131 and functional status in extensive alopecia areata (EAA) scalp skin.

132 One patient with extensive alopecia areata experienced skin atrophy that resolved spontaneou

133 was distributed using the National Alopecia Areata Foundation (NAAF) with the aim of assessing (1) p

134 C3H/HeJ mice spontaneously develop alopecia areata from 5 mo of age and older in females and later i

135 Few treatments for alopecia areata have been well evaluated in randomized trials.

136 healthy controls and patients with alopecia areata, identifying diverse cell types of the hair folli

137 st treatment for adults with severe alopecia areata in 2022 and for adolescents with severe alopecia

138 022 and for adolescents with severe alopecia areata in 2023, with multiple investigational treatments

139 rize a new high-incidence model for alopecia areata in C57BL/6J mice, the first to our knowledge to a

140 that is known to be associated with alopecia areata in humans.

141 (+) T effector memory cells mediate alopecia areata in part through Janus kinase (JAK) signaling and

142 be a suitable treatment option for alopecia areata in patients who are candidates for systemic thera

143 port a previously proposed model of alopecia areata in which immunity is directed against melanogenes

144 tis, inflammatory bowel disease and alopecia areata, in which stimulation of innate immunity activate

145 amaging variants in 51 heterozygous Alopecia Areata individuals (6.01%), achieving genome-wide signif

146 Consensus was reached that the Alopecia Areata Investigator Global Assessment scale adequately c

147 These results suggest alopecia areata is a cell-mediated autoimmune disease, but alopec

148 Alopecia areata is a common cause of non-scaring autoimmune hair

149 Alopecia areata is a complex genetic disease that results in hair

150 Alopecia areata is a suspected autoimmune hair loss disease.

151 Alopecia areata is accompanied by Th2/Tc2 activation in skin-homi

152 Alopecia areata is among the most prevalent autoimmune diseases,

153 Alopecia areata is an autoimmune disease in which loss of immune

154 Alopecia areata is an autoimmune disease that targets actively gr

155 Alopecia areata is an idiopathic cause of hair loss with limited

156 Alopecia areata is an immune-mediated, nonscarring form of hair l

157 Alopecia areata is an inflammatory hair loss disease with a major

158 Alopecia areata is characterised by non-scarring loss of scalp, f

159 cy of currently used treatments for alopecia areata is lacking.

160 Alopecia areata is less common, but may be distressing, especiall

161 control study seem to indicate that alopecia areata is modulated by natural hair color, preferentiall

162 Alopecia areata is one of the most frequent organ-restricted auto

163 ve been implicated, the genetics of alopecia areata is still unclear.

164 stion regarding the pathogenesis of alopecia areata is the potential linkage with the brain.

165 nus kinase (JAK) signaling and that alopecia areata might be treated with JAK inhibitors.

166 8), atopic dermatitis (n = 30 418), alopecia areata (n = 17 889), vitiligo (n = 7735), or HS (n = 593

167 0), androgenetic alopecia (n = 52), alopecia areata (n = 17), and alopecia areata totalis/universalis

168 Alopecia areata (n=138) and clinically normal (n=214) mice were g

169 ering all patients with any form of alopecia areata, no association was found with IL-1RN.

170 In addition, although alopecia areata often results in significant psychological distre

171 d skin grafts but failed to develop alopecia areata, only two of 22 receiving further alopecia areata

172 Alopecia areata onset could be inhibited in skin-grafted mice by

173 ffected skin graft hosts may resist alopecia areata onset through active counter-regulatory mechanism

174 the contribution from mild cases of alopecia areata [OR 1.48 (0.96, 2.29)], suggesting that IL-1 alph

175 between IL1-RN*1 allele and patchy alopecia areata (p =0.045).

176 cell-mediated disease mechanism in alopecia areata pathogenesis and suggested targeting antigen-pres

177 Three PROMs (Alopecia Areata Patient Priority Outcomes [AAPPO], Alopecia Areat

178 and its expression is decreased in Alopecia Areata patient skin and hair follicles.

179 vel burden analyses approach on 849 Alopecia Areata patients compared to 15,640 controls.

180 Alopecia areata patients with and without concomitant atopic derm

181 a Areata Quality of Life Index, and Alopecia Areata Patients' Quality of Life) were AA-specific healt

182 syndrome, Crohn disease, vitiligo, alopecia areata, pernicious anemia, ulcerative colitis, rheumatoi

183 haired littermates transferred the alopecia areata phenotype.

184 In this paper, we analyzed alopecia areata probands in a family-based sample (n = 131 parent

185 Treatment reduced skin pathology in alopecia areata, psoriasis, and atopic dermatitis, while decreasi

186 (Scale of Alopecia Areata Distress, Alopecia Areata Quality of Life Index, and Alopecia Areata Patien

187 ate possible mechanisms involved in alopecia areata resistance.

188 Because alopecia areata resistant mice showed unimpaired responsiveness a

189 In contrast, alopecia areata resistant mouse skin did not display increased nu

190 D44v variants, and FasL occurred in alopecia areata resistant mouse spleens.

191 KRT82 is identified as an Alopecia Areata risk gene with rare damaging variants in 51 heter

192 ele was found to be associated with alopecia areata severity in a British case-control study.

193 Patient Priority Outcomes [AAPPO], Alopecia Areata Severity Self-Assessment, and Alopecia Areata Sym

194 ASDs, including alopecia areata, Sjogren syndrome, vitiligo, cutaneous lupus eryt

195 d resistance locus) did not develop alopecia areata, supporting this locus as being important in alop

196 a, but high dietary soy oil reduces alopecia areata susceptibility.

197 reata Severity Self-Assessment, and Alopecia Areata Symptom Impact Scale) were based on both construc

198 diseases, ranging from psoriasis to alopecia areata to vitiligo to lupus erythematosus to atopic derm

199 have been reported in patients with alopecia areata totalis (AT) or universalis (AU), the most severe

200 effluvium (50.1 [33.9, 66.33]) and alopecia areata totalis/universalis (52.3 [23.1, 81.5]) were not

201 52), alopecia areata (n = 17), and alopecia areata totalis/universalis (n = 7).

202 ive lymphocytes may be effective in alopecia areata treatment.

203 ge and sex to 6692 controls without alopecia areata using 1:4 matching.

204 ntify rare variants contributing to Alopecia Areata using a whole exome sequencing and gene-level bur

205 ses, including lupus erythematosus, alopecia areata, vitiligo, and lichen planus.

206 orded psoriasis, atopic dermatitis, alopecia areata, vitiligo, or hidradenitis suppurativa were inclu

207 of dermatological diseases such as alopecia areata, vitiligo, psoriasis and atopic dermatitis, commo

208 nd the mean (SD) age for those with alopecia areata was 46.9 (16.5) years.

209 Alopecia areata was associated with moderate (OR, 5.23; 95% CI, 1

210 Alopecia areata was identified based on having at least 1 diagnos

211 Alopecia areata was significantly more common in individuals with

212 gate the role of the IL-1 system in alopecia areata we examined three biallelic polymorphisms within

213 pruritus, scabies, cellulitis, and alopecia areata were underrepresented in CDSR when matched with c

214 d mice with and without spontaneous alopecia areata, were similarly processed.

215 eata affected skin grafts developed alopecia areata, whereas 39 of 44 controls developed alopecia are

216 ng these individuals, 1673 cases of alopecia areata with reported hair color were captured and matche

217 terized by loss of hair in patches (alopecia areata) with progression in some individuals to total lo